AUGMEDIX INC (AUGX) Fundamental Analysis & Valuation

NASDAQ:AUGX • US05105P1075

Current stock price

2.35 USD
0 (0%)
At close:
2.35 USD
0 (0%)
After Hours:

This AUGX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. AUGX Profitability Analysis

1.1 Basic Checks

  • AUGX had negative earnings in the past year.
  • AUGX had a negative operating cash flow in the past year.
  • AUGX had negative earnings in each of the past 5 years.
  • AUGX had a negative operating cash flow in each of the past 5 years.
AUGX Yearly Net Income VS EBIT VS OCF VS FCFAUGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

  • AUGX has a Return On Assets of -44.44%. This is in the lower half of the industry: AUGX underperforms 65.79% of its industry peers.
  • With a Return On Equity value of -227.72%, AUGX is not doing good in the industry: 81.58% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -44.44%
ROE -227.72%
ROIC N/A
ROA(3y)-44.98%
ROA(5y)-61.67%
ROE(3y)-606%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AUGX Yearly ROA, ROE, ROICAUGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

  • The Gross Margin of AUGX (48.21%) is worse than 60.53% of its industry peers.
  • AUGX's Gross Margin has improved in the last couple of years.
  • AUGX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.22%
GM growth 5Y45.73%
AUGX Yearly Profit, Operating, Gross MarginsAUGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -50 -100 -150 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. AUGX Health Analysis

2.1 Basic Checks

  • AUGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, AUGX has more shares outstanding
  • AUGX has a better debt/assets ratio than last year.
AUGX Yearly Shares OutstandingAUGX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
AUGX Yearly Total Debt VS Total AssetsAUGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

  • AUGX has an Altman-Z score of -2.71. This is a bad value and indicates that AUGX is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -2.71, AUGX is doing worse than 65.79% of the companies in the same industry.
  • A Debt/Equity ratio of 1.48 is on the high side and indicates that AUGX has dependencies on debt financing.
  • The Debt to Equity ratio of AUGX (1.48) is worse than 84.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.48
Debt/FCF N/A
Altman-Z -2.71
ROIC/WACCN/A
WACC9%
AUGX Yearly LT Debt VS Equity VS FCFAUGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

  • AUGX has a Current Ratio of 1.66. This is a normal value and indicates that AUGX is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of AUGX (1.66) is comparable to the rest of the industry.
  • AUGX has a Quick Ratio of 1.66. This is a normal value and indicates that AUGX is financially healthy and should not expect problems in meeting its short term obligations.
  • AUGX has a Quick ratio (1.66) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
AUGX Yearly Current Assets VS Current LiabilitesAUGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. AUGX Growth Analysis

3.1 Past

  • AUGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.66%, which is quite good.
  • The Revenue has grown by 39.34% in the past year. This is a very strong growth!
  • AUGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 32.90% yearly.
EPS 1Y (TTM)15.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.33%
Revenue 1Y (TTM)39.34%
Revenue growth 3Y39.62%
Revenue growth 5Y32.9%
Sales Q2Q%26.75%

3.2 Future

  • AUGX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.46% yearly.
  • The Revenue is expected to grow by 11.58% on average over the next years. This is quite good.
EPS Next Y-20.13%
EPS Next 2Y-3.76%
EPS Next 3Y6.46%
EPS Next 5YN/A
Revenue Next Year18.97%
Revenue Next 2Y22.71%
Revenue Next 3Y11.58%
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
AUGX Yearly Revenue VS EstimatesAUGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M
AUGX Yearly EPS VS EstimatesAUGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

0

4. AUGX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AUGX. In the last year negative earnings were reported.
  • Also next year AUGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AUGX Price Earnings VS Forward Price EarningsAUGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AUGX Per share dataAUGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.76%
EPS Next 3Y6.46%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AUGX Dividend Analysis

5.1 Amount

  • No dividends for AUGX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

AUGX Fundamentals: All Metrics, Ratios and Statistics

AUGMEDIX INC

NASDAQ:AUGX (10/1/2024, 8:00:01 PM)

After market: 2.35 0 (0%)

2.35

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)08-12
Earnings (Next)11-04
Inst Owners72.68%
Inst Owner Change0%
Ins Owners11.72%
Ins Owner Change0%
Market Cap116.16M
Revenue(TTM)51.59M
Net Income(TTM)-23.85M
Analysts80
Price Target3.6 (53.19%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.31%
Min EPS beat(2)4.41%
Max EPS beat(2)12.2%
EPS beat(4)4
Avg EPS beat(4)11.24%
Min EPS beat(4)4.41%
Max EPS beat(4)16.56%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.48%
Min Revenue beat(2)-1.76%
Max Revenue beat(2)-1.2%
Revenue beat(4)1
Avg Revenue beat(4)-0.56%
Min Revenue beat(4)-1.76%
Max Revenue beat(4)0.98%
Revenue beat(8)4
Avg Revenue beat(8)0.08%
Revenue beat(12)5
Avg Revenue beat(12)-0.26%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.74%
EPS NY rev (1m)0%
EPS NY rev (3m)1.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.06%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.25
P/FCF N/A
P/OCF N/A
P/B 11.09
P/tB 11.09
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS1.04
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.44%
ROE -227.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.21%
FCFM N/A
ROA(3y)-44.98%
ROA(5y)-61.67%
ROE(3y)-606%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.22%
GM growth 5Y45.73%
F-Score5
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 1.48
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 180.82%
Cap/Sales 4.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z -2.71
F-Score5
WACC9%
ROIC/WACCN/A
Cap/Depr(3y)178.38%
Cap/Depr(5y)139.24%
Cap/Sales(3y)4.74%
Cap/Sales(5y)4.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.33%
EPS Next Y-20.13%
EPS Next 2Y-3.76%
EPS Next 3Y6.46%
EPS Next 5YN/A
Revenue 1Y (TTM)39.34%
Revenue growth 3Y39.62%
Revenue growth 5Y32.9%
Sales Q2Q%26.75%
Revenue Next Year18.97%
Revenue Next 2Y22.71%
Revenue Next 3Y11.58%
Revenue Next 5YN/A
EBIT growth 1Y-14.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-19.28%
EBIT Next 3Y9.53%
EBIT Next 5YN/A
FCF growth 1Y12.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.91%
OCF growth 3YN/A
OCF growth 5YN/A

AUGMEDIX INC / AUGX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for AUGMEDIX INC?

ChartMill assigns a fundamental rating of 2 / 10 to AUGX.


What is the valuation status of AUGMEDIX INC (AUGX) stock?

ChartMill assigns a valuation rating of 0 / 10 to AUGMEDIX INC (AUGX). This can be considered as Overvalued.


Can you provide the profitability details for AUGMEDIX INC?

AUGMEDIX INC (AUGX) has a profitability rating of 1 / 10.


What is the expected EPS growth for AUGMEDIX INC (AUGX) stock?

The Earnings per Share (EPS) of AUGMEDIX INC (AUGX) is expected to decline by -20.13% in the next year.